Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: van Treijen M
Authors: van Treijen M, van der Zee D, Heeres B, Staal F, Vriens M,
Keywords: biomarker, progression-free survival, gastro-entero-pancreatic neuroendocrine tumours,
Introduction: There is a substantial clinical unmet need for an accurate blood biomarker for neuroendocrine neoplasms (NENs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Malczewska A
Authors: Malczewska A, Witkowska M, Wojcik-Giertuga M, Bocian A, Walter A,
Keywords: NETest, liquid biopsy, neuroendocrine, GEP-NEN, BPNEN, CgA, biomarker,
#2202 Assessment of the Clinical Utility of the NETest in a US Registry-Based Study
Introduction: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancer. Current biomarkers in NET disease have limited clinical utility.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Bodei L
Authors: Liu E, Paulson S, Gulati A, Freudman J, Grosh W,
Keywords: Registry, biomarker, NETest, GEP-NET, Monitor, Treatment, Predict,
Introduction: The identification and characterization of CTCs as part of a minimally invasive “liquid biopsy” provides an opportunity to explore NET biology, identify therapeutic targets and investigate tumour heterogeneity.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Childs A
Authors: Childs A, Vesely C, Rizzo F, Ensell L, Lowe H,
Keywords: CTCs, tumor heterogeneity, CNV,
Introduction: Cell-free DNA (cfDNA) as a type of “liquid biopsy” represents an attractive alternative to tissue sampling for detecting tumour-specific changes (circulating tumour DNA; ctDNA).
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Pipinikas C
Authors: Pipinikas C, Gutteridge A, Forshew T, Childs A, Meyer T,